Semaglutide optic neuropathy: correction

On 6 July 2026, JCEM Case Reports issued a formal correction to its May 2026 case report on atypical retrobulbar optic neuropathy following semaglutide dose escalation^[1]. The erratum corrects the original article by Channabasappa and colleagues (PMID 42220603), which documented an unusual pattern of optic nerve injury in a man in his early 30s four weeks after reaching semaglutide 1 mg weekly^[2]. Published errata are a normal part of scientific publishing. They confirm that the journal has reviewed and updated the official record; they do not retract or invalidate the underlying clinical case.

What the correction covers

The published erratum references the correction without specifying which text was changed. This is the standard format for errata that address minor factual, formatting, or attribution errors rather than the clinical findings themselves^[1]. The clinical details of the case (patient profile, optic findings, the outcome after discontinuation) were reported in the original article and remain part of the peer-reviewed record. Readers seeking the clinical content should consult the corrected version of the original article at DOI 10.1210/jcemcr/luag108.

When a journal issues an erratum, PubMed links the correction notice to the original article, and the corrected version becomes the version of record. The correction does not remove the original from the literature or change the citation count. It signals that the authors or editors identified something that needed updating, and the journal process responded appropriately.

A brief recap of the original case

The original case described a man in his early 30s with class III obesity, obstructive sleep apnea, and prediabetes who developed acute, painless, asymmetric bilateral visual dysfunction four weeks after his semaglutide dose reached 1 mg weekly^[2]. Both optic discs appeared normal on examination, which made this presentation atypical. Visual evoked potentials showed markedly delayed signals in both eyes, pointing to retrobulbar injury (behind the eyeball rather than at the disc). MRI of the brain and orbits was unremarkable.

Blood work including inflammatory markers, vitamin B12, and thyroid function was all within normal limits. The clinical team considered demyelinating optic neuritis and NAION before concluding that the presentation was most consistent with drug-related retrobulbar optic neuropathy. Vision stabilized after semaglutide was stopped, though a central scotoma in the left eye persisted at follow-up^[2]. The authors called for clinical vigilance and strengthened pharmacovigilance as GLP-1 receptor agonist use expands globally.

Why this presentation was unusual

Most of the published discussion on semaglutide and eye safety since 2024 has focused on non-arteritic anterior ischemic optic neuropathy (NAION), a condition where the injury is anterior and the optic disc typically appears swollen. The Channabasappa case was different: the optic discs were visually normal throughout, and the damage was detectable only through electrophysiology. The authors suggested this meant the spectrum of potential optic nerve effects with GLP-1 receptor agonists may be broader than NAION alone^[2]. For clinicians using standard fundoscopy before prescribing GLP-1 receptor agonists, the case raises the question of whether examining only the disc is enough to detect retrobulbar pathology.

What the broader evidence shows

The semaglutide-and-vision question has attracted a significant volume of research since 2024. A 2026 systematic review and meta-analysis by Lampsas and colleagues, drawing on over 14 million participants across eight retrospective cohorts, found a hazard ratio of 3.36 for NAION at one year and 2.37 at both two and five years in type 2 diabetes patients on semaglutide^[3]. A separate 2026 systematic review across 28 observational studies by Anatriello and colleagues reached a different conclusion: no statistically significant increase in overall ocular disorder risk when GLP-1 receptor agonists were compared with other antidiabetic treatments, with a recommendation for continued monitoring^[4]. These two bodies of evidence sit in tension, and the discrepancy likely reflects differences in study design, population, and outcome definitions.

A 2025 joint consensus statement from the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology acknowledged the possible association between GLP-1 receptor agonists and NAION but noted that other studies had found no correlation and that the absolute risk remains low. Their recommendation was shared decision-making between patient and clinician, not blanket avoidance of the drug class. You can read more about the semaglutide regulatory profile on the main peptide page.

What we do not yet know

A single case report cannot establish causation, and a correction to that case report changes even less about what is known. The patient had multiple independent vascular risk factors (severe obesity, sleep apnea, prediabetes, dyslipidaemia) that predispose to optic neuropathy on their own. Whether semaglutide contributed directly, accelerated a process already underway, or was coincidental is impossible to determine from one patient. No rechallenge was attempted, so there is no way to say whether restarting the drug would reproduce the problem.

The proposed mechanism in the original report (altered optic nerve perfusion and disrupted vascular autoregulation) is plausible but unproven in prospective studies. Whether the rapid dose escalation schedule played a role, or whether slower titration would carry a different risk profile, is also unknown. Prospective registries tracking optic events in GLP-1 receptor agonist users would help answer that question, but none have reported results as of this writing.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. If you are taking semaglutide and notice any change in vision, report it to your prescriber promptly. Always consult a qualified healthcare professional before making any decision about your treatment.